Ionis Pharmaceuticals Announces Positive Two-Year Data for Diranersen in Alzheimer's Disease
Ionis Pharmaceuticals and its partner Biogen reported new two-year data from the Phase 2 CELIA study showing clinical benefit for diranersen in early Alzheimer's disease.